SWHR Statement on President’s Fiscal Year 2023 Budget
March 30, 2022 – The Society for Women’s Health Research issued the following statement in response to the Office of Management and Budget’s release of the president’s budget for fiscal year 2023.
The Society for Women’s Health Research (SWHR) values President Biden’s continued commitment to scientific advancement and appreciates the administration’s proposed investments for the nation’s public health and research agencies in fiscal year 2023. Over the past three years, we have been acutely reminded of the critical role that these entities have in ensuring the health and well-being of individuals and communities across the country, and we must continue to ensure they are prioritized in annual spending legislation.
While SWHR was grateful for the budget’s emphasis on science—through proposed funding increases at federal research agencies, including at the Centers for Disease Control and Prevention (CDC), Agency for Healthcare Research and Quality (AHRQ), and Food and Drug Administration (FDA), as well as new scientific programs and initiatives—we were disappointed in the low increase provided to the National Institutes of Health (NIH).
Sustained, robust investments in our nation’s federal research agencies help ensure that they can keep up with inflation, fund groundbreaking research that fills knowledge gaps and responds to public health needs, and ultimately fulfill their promise to the American people. The funding level proposed for NIH in the president’s budget is insufficient; if enacted, the agency could miss an important opportunity—at a critical point in time—to help our nation respond to future public health threats and provide insight on prevention, treatment, and cures for the diseases and conditions that affect Americans.
SWHR commends the budget request’s historical investments in pandemic preparedness and biodefense, the increased investment in the Advanced Research Projects Agency for Health (ARPA-H) that would foster transformative health research, dedicated funding targeted at combatting maternal morbidity and mortality, and the funding boosts provided to various federal research agencies. Through investments such as these, the administration is upholding its promise for science to be at the forefront of decision-making and policy. Still, we must ensure that agencies continue to receive sustained funding increases so they can advance their respective missions, deliver knowledge advancement and application, and ultimately improve health outcomes for the American people.
SWHR looks forward to working with the administration and Congress to build upon the president’s fiscal year 2023 budget request, strengthening funding for our nation’s public health and research agencies and institutes. We stand ready to assist the administration and congressional champions to advocate for prioritized and sustained investments in women’s health research across the lifespan.
Contact SWHR Chief Advocacy Officer Lindsey Horan with questions.
March 30, 2022 – The Society for Women’s Health Research issued the following statement in response to the Office of Management and Budget’s release of the president’s budget for fiscal year 2023.
The Society for Women’s Health Research (SWHR) values President Biden’s continued commitment to scientific advancement and appreciates the administration’s proposed investments for the nation’s public health and research agencies in fiscal year 2023. Over the past three years, we have been acutely reminded of the critical role that these entities have in ensuring the health and well-being of individuals and communities across the country, and we must continue to ensure they are prioritized in annual spending legislation.
While SWHR was grateful for the budget’s emphasis on science—through proposed funding increases at federal research agencies, including at the Centers for Disease Control and Prevention (CDC), Agency for Healthcare Research and Quality (AHRQ), and Food and Drug Administration (FDA), as well as new scientific programs and initiatives—we were disappointed in the low increase provided to the National Institutes of Health (NIH).
Sustained, robust investments in our nation’s federal research agencies help ensure that they can keep up with inflation, fund groundbreaking research that fills knowledge gaps and responds to public health needs, and ultimately fulfill their promise to the American people. The funding level proposed for NIH in the president’s budget is insufficient; if enacted, the agency could miss an important opportunity—at a critical point in time—to help our nation respond to future public health threats and provide insight on prevention, treatment, and cures for the diseases and conditions that affect Americans.
SWHR commends the budget request’s historical investments in pandemic preparedness and biodefense, the increased investment in the Advanced Research Projects Agency for Health (ARPA-H) that would foster transformative health research, dedicated funding targeted at combatting maternal morbidity and mortality, and the funding boosts provided to various federal research agencies. Through investments such as these, the administration is upholding its promise for science to be at the forefront of decision-making and policy. Still, we must ensure that agencies continue to receive sustained funding increases so they can advance their respective missions, deliver knowledge advancement and application, and ultimately improve health outcomes for the American people.
SWHR looks forward to working with the administration and Congress to build upon the president’s fiscal year 2023 budget request, strengthening funding for our nation’s public health and research agencies and institutes. We stand ready to assist the administration and congressional champions to advocate for prioritized and sustained investments in women’s health research across the lifespan.
Contact SWHR Chief Advocacy Officer Lindsey Horan with questions.